Challenges in the treatment of cystic fibrosis in the era of CFTR modulatorsAuthors' replyUse of elexacaftor+tezacaftor+ivacaftor in individuals with cystic fibrosis and at least one F508del allele a systematic review and meta-analysisDiscontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY) results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trialsAssessing Safety of Discontinuing Hypertonic Saline in Those with Lower Forced Expiratory Volume in 1 Second after Elexacaftor/Tezacaftor/Ivacaftor.
Caroline Jacoby SchmidtLaura Silveira de MouraPaulo de Tarso Roth DalcinBruna ZieglerPublished in: Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia (2024)
Keyphrases
- cystic fibrosis
- pseudomonas aeruginosa
- open label
- study protocol
- lung function
- clinical trial
- replacement therapy
- phase ii
- squamous cell carcinoma
- mechanical ventilation
- phase iii
- chronic obstructive pulmonary disease
- phase ii study
- combination therapy
- acute respiratory distress syndrome
- extracorporeal membrane oxygenation